A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Depression; Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms TRANSFORM-1
- Sponsors Janssen Research & Development
- 17 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2017 The study has been completed in Hungary (End date: 2017-10-20).
- 22 Jul 2017 This trial has been discontinued in Poland